Efficacy and safety of factor VIII inhibitor by-passing activity (FEIBA) in high thrombotic risk patients with acquired haemophilia (AH)

被引：0
|
作者：
Gamba, G. [1 ]
Montani, N. [1 ]
Trinchero, A. [1 ]
Pecci, A. [1 ]
Bertolino, G. P. [1 ]
Lodo, F. [1 ]
机构：
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Internal Med, Haemophilia Ctr, I-27100 Pavia, Italy
来源：
HAEMOPHILIA | 2010年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [21] Factor VIII inhibitor bypass activity (Feiba) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors.
    Kreutz, W
    Escuriola-Ettinghausen, C
    Mentzer, D
    Martinez, I
    Becker, S
    Stoll, H
    Heller, C
    BLOOD, 2000, 96 (11) : 266A - 266A
  • [22] Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors
    Lauroua, P.
    Ferrer, A. -M.
    Guerin, V.
    HAEMOPHILIA, 2009, 15 (06) : 1300 - 1307
  • [23] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [24] SAFETY AND EFFICACY OF HIGH-DOSE, PLASMA-DERIVED FVIII IN PATIENTS WITH ACQUIRED HAEMOPHILIA A
    Di Prinzio, G.
    Goldmann, G.
    Horneff, S.
    Klein, C.
    Marquardt, N.
    Nadal, J.
    Oldenburg, J.
    HAEMOPHILIA, 2021, 27 : 127 - 127
  • [25] Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor
    Croteau, S. E.
    Abajas, Y. L.
    Wolberg, A. S.
    Nielsen, B. I.
    Marx, G. R.
    Baird, C. W.
    Neufeld, E. J.
    Monahan, P. E.
    HAEMOPHILIA, 2017, 23 (02) : E93 - E98
  • [26] Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients
    Spira, Jack
    Plyushch, Olga
    Andreeva, Tatiana
    Zorenko, Vladimir
    Zozulya, Nadezhda
    Velichkoi, Irena
    Zalepukhina, Olga Ervinovna
    Yatuv, Rivka
    Baru, Moshe
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (01) : 149 - 152
  • [27] Safety and efficacy of a sucrose-formulated recombinant Factor VIII in previously untreated or minimally treated haemophilia A patients
    Kreuz, W
    Gazengel, C
    Gorina, E
    Kellermann, E
    THROMBOSIS AND HAEMOSTASIS, 1999, : 131 - 131
  • [28] The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update
    Lusher, JM
    Roth, DA
    HAEMOPHILIA, 2005, 11 (03) : 292 - 293
  • [29] Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study
    Holstein, Katharina
    Smith, Andrea
    Knobl, Paul
    Dobbelstein, Christiane
    Miesbach, Wolfgang A.
    Spannagl, Michael
    Heinz, Jurgen
    Scholz, Ute
    Eichler, Hermann
    Huth-Kuhne, Angela
    Klamroth, Robert
    Koch, Armin
    Tiede, Andreas
    BLOOD, 2017, 130
  • [30] Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII
    Gringeri, A
    Tagliaferri, A
    Tagariello, G
    Morfini, M
    Santagostino, E
    Mannucci, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (03) : 398 - 404
12345